CeriBell, Inc. CBLL

Company Overview

Ceribell, Inc. (NASDAQ: CBLL) is a medical technology company focused on rapid electroencephalography (EEG) systems designed for point-of-care neurological monitoring. The company operates within the healthcare technology and neurodiagnostics industries, with products primarily intended to assist clinicians in detecting seizures and other acute neurological conditions in emergency departments, intensive care units, and hospital settings where conventional EEG infrastructure may be limited or unavailable. Its core commercial offering is the Ceribell System, which combines a portable EEG headband, proprietary hardware, cloud-connected software, and artificial intelligence-enabled seizure detection tools.

The company’s primary revenue drivers are sales and recurring usage associated with its EEG platform, including disposable components, software subscriptions, and hospital deployments. Ceribell’s strategic positioning is centered on reducing the time required to diagnose non-convulsive seizures and enabling broader access to EEG monitoring beyond traditional neurology departments. The company was founded in 2014 by clinicians and researchers affiliated with Stanford University and has evolved from an early-stage neurodiagnostics startup into a publicly traded commercial-stage medtech company focused on acute neurological care.